LA
OACC

Linden Advisors’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Linden Advisors’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.37M Hold
600,000
– – 0.04% 252
2025
Q4 		$6.38M Hold
600,000
– – 0.04% 225
2025
Q3 		$6.28M Hold
600,000
– – 0.04% 200
2025
Q2 		$6.29M Hold
600,000
– – 0.04% 204
2025
Q1 		$6.12M Buy
+600,000
New +$6.02M 0.04% 178

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Linden Advisors's OACC Position: Q1 2026 in Review

Linden Advisors held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q1 2026 at 600,000 shares worth $6.37M. The position accounts for 0.04% of the portfolio, ranked #252.

Linden Advisors first reported a position in OACC in Q1 2025 and has held it in 5 quarters since. The position peaked at $6.38M in Q4 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Linden Advisors held 600,000 shares of Oaktree Acquisition Corp III Life Sciences worth $6.37M as of Q1 2026.
  • Linden Advisors left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences made up 0.04% of Linden Advisors's portfolio in Q1 2026, its #252 holding.
  • Linden Advisors first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 5 quarters since.
  • Linden Advisors's Oaktree Acquisition Corp III Life Sciences position peaked at $6.38M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Linden Advisors's 13F filing for Q1 2026, filed 15 May 2026.